{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:30:47Z","timestamp":1769189447271,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.10.010","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T18:55:26Z","timestamp":1698692126000},"page":"177-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-8160","authenticated-orcid":false,"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth S.","family":"Mearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen D.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Lamarre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1216-7053","authenticated-orcid":false,"given":"Archibong","family":"Yellow-Duke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neda","family":"Alrawashdh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cat N.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0880-1853","authenticated-orcid":false,"given":"Anders","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.10.010_bib0001","unstructured":"Leukemia & Lymphoma Society. Myelodysplastic syndrome (MDS) research funded by LLS. 2023. Available at: https:\/\/www.lls.org\/research\/myelodysplastic-syndrome-mds-research-funded-lls Accessed: April 20, 2023."},{"key":"10.1016\/j.clml.2023.10.010_bib0002","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.clml.2018.02.001","article-title":"Systematic literature review of treatment options and clinical outcomes for patients with higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"18","author":"Bell","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.10.010_bib0003","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.2217\/fon-2022-0334","article-title":"Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes","volume":"18","author":"Kota","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2023.10.010_bib0004","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.010_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2013-08-496935","article-title":"How we treat higher-risk myelodysplastic syndromes","volume":"123","author":"Sekeres","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.010_bib0006","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MOH.0000000000000016","article-title":"Beyond hypomethylating agents failure in patients with myelodysplastic syndromes","volume":"21","author":"Zeidan","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2023.10.010_bib0007","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.blre.2005.01.004","article-title":"Myelodysplastic syndromes: a comprehensive review","volume":"19","author":"Catenacci","year":"2005","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2023.10.010_bib0008","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/hematology.2019000042","article-title":"In MDS, is higher risk higher reward?","volume":"1","author":"Sanz","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2023.10.010_bib0009","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","article-title":"NCCN Guidelines\u00ae insights: myelodysplastic syndromes, version 3.2022","volume":"20","author":"Greenberg","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2023.10.010_bib0010","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/cedazuridine: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2023.10.010_bib0011","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.10.010_bib0012","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.010_bib0013","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.10.010_bib0014","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.clml.2023.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.010_bib0016","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjh.15273","article-title":"Azacitidine in the \u2018real-world\u2019: an evaluation of 1101 higher-risk myelodysplastic syndrome\/low blast count acute myeloid leukaemia patients in Ontario, Canada","volume":"181","author":"Mozessohn","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.10.010_bib0017","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/leu.2015.115","article-title":"Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry","volume":"29","author":"Bernal","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.10.010_bib0018","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/leu.2015.220","article-title":"Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry","volume":"29","author":"Dinmohamed","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.10.010_bib0019","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/10428194.2019.1703970","article-title":"Hypomethylating agent (HMA) therapy use and survival in older adults with refractory anemia with excess blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study(\u2020)","volume":"61","author":"Davidoff","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.10.010_bib0020","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1080\/10428194.2020.1869959","article-title":"Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis","volume":"62","author":"Stein","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.10.010_bib0021","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ad\u00e8s","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.10.010_bib0022","doi-asserted-by":"crossref","first-page":"11032","DOI":"10.1182\/blood-2022-157666","article-title":"Burden of illness in patients with higher-risk myelodysplastic syndromes by baseline transfusion status","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.010_bib0023","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.leukres.2015.05.007","article-title":"Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes","volume":"39","author":"Balleari","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2023.10.010_bib0024","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model","volume":"29","author":"Naqvi","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T06:07:03Z","timestamp":1709878023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021584"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}